Quoin Pharmaceuticals (QNRX) Share-based Compensation (2020 - 2026)

Quoin Pharmaceuticals has disclosed Share-based Compensation across 7 years of filings, most recently posting $6.8 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 513.63% year-over-year to $6.8 million; the TTM figure through Jun 2026 stood at $6.8 million (up 513.63% YoY), while the FY2025 annual figure was $2.5 million, down 13.79% from the prior year.
• Share-based Compensation came in at $6.8 million for Q2 2026 at Quoin Pharmaceuticals, down from $7.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.4 million in Q1 2023 to a low of $267007.0 in Q4 2022.
• Average Share-based Compensation over 5 years is $4.0 million, with a median of $2.5 million recorded in 2025.
• Year-over-year, Share-based Compensation jumped 2233.98% in 2022 and plunged 89.18% in 2025.
• Over 5 years, Share-based Compensation stood at $267007.0 in 2022, then climbed by 12.43% to $300198.0 in 2023, then advanced by 8.93% to $327000.0 in 2024, then slipped by 12.55% to $285969.0 in 2025, then soared by 2277.88% to $6.8 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $6.8 million in Q2 2026, $7.3 million in Q1 2026, and $285969.0 in Q4 2025.